146 related articles for article (PubMed ID: 38745113)
1. Beneficial effects of maintaining liver function during hepatic arterial infusion chemotherapy combined with tyrosine kinase and programmed cell death protein-1 inhibitors on the outcomes of patients with unresectable hepatocellular carcinoma.
Xiao Y; Deng W; Luo L; Zhu G; Xie J; Liu Y; Wan R; Wen W; Hu Z; Shan R
BMC Cancer; 2024 May; 24(1):588. PubMed ID: 38745113
[TBL] [Abstract][Full Text] [Related]
2. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma.
Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Xu HF; Gao QZ; Yang RJ
Immunotherapy; 2021 Dec; 13(17):1395-1405. PubMed ID: 34607482
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.
Zhang Y; Zhang H; Xu H; Wang Y; Feng L; Yi F
World J Surg Oncol; 2024 May; 22(1):122. PubMed ID: 38711095
[TBL] [Abstract][Full Text] [Related]
4. Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis.
Cao YZ; Zheng GL; Zhang TQ; Shao HY; Pan JY; Huang ZL; Zuo MX
World J Gastroenterol; 2024 Jan; 30(4):318-331. PubMed ID: 38313229
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of targeted therapy plus immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX) for unresectable hepatocarcinoma.
Lin ZP; Hu XL; Chen D; Huang DB; Zou XG; Zhong H; Xu SX; Chen Y; Li XQ; Zhang J
World J Gastroenterol; 2024 May; 30(17):2321-2331. PubMed ID: 38813052
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
[TBL] [Abstract][Full Text] [Related]
7. Impact of Immune Checkpoint Inhibitors with or without a Combination of Tyrosine Kinase Inhibitors on Organ-Specific Efficacy and Macrovascular Invasion in Advanced Hepatocellular Carcinoma.
Kuo HY; Chiang NJ; Chuang CH; Chen CY; Wu IC; Chang TT; Tsai HM; Lin YJ
Oncol Res Treat; 2020; 43(5):211-220. PubMed ID: 32101878
[TBL] [Abstract][Full Text] [Related]
8. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience.
Luo L; Xiao Y; Zhu G; Huang A; Song S; Wang T; Ge X; Xie J; Deng W; Hu Z; Wen W; Mei H; Wan R; Shan R
Front Oncol; 2022; 12():1004652. PubMed ID: 36237309
[TBL] [Abstract][Full Text] [Related]
9. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification.
Miyaki D; Aikata H; Honda Y; Naeshiro N; Nakahara T; Tanaka M; Nagaoki Y; Kawaoka T; Takaki S; Waki K; Hiramatsu A; Takahashi S; Ishikawa M; Kakizawa H; Awai K; Chayama K
J Gastroenterol Hepatol; 2012 Dec; 27(12):1850-7. PubMed ID: 23020312
[TBL] [Abstract][Full Text] [Related]
10. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
Xu YJ; Lai ZC; He MK; Bu XY; Chen HW; Zhou YM; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M; Li QJ
Technol Cancer Res Treat; 2021; 20():15330338211063848. PubMed ID: 34898313
[No Abstract] [Full Text] [Related]
11. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study.
Zang M; Hu X; Yuan G; Li R; Li W; Pang H; Li Q; Chen J
Int Immunopharmacol; 2023 Dec; 125(Pt A):111019. PubMed ID: 37879230
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method.
Fukubayashi K; Tanaka M; Izumi K; Watanabe T; Fujie S; Kawasaki T; Yoshimaru Y; Tateyama M; Setoyama H; Naoe H; Kikuchi K; Sasaki Y
Cancer Med; 2015 Aug; 4(8):1214-23. PubMed ID: 26044168
[TBL] [Abstract][Full Text] [Related]
14. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
[TBL] [Abstract][Full Text] [Related]
15. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
Ke Q; Xin F; Fang H; Zeng Y; Wang L; Liu J
Front Immunol; 2022; 13():913464. PubMed ID: 35677059
[TBL] [Abstract][Full Text] [Related]
16. Response to chemotherapy improves hepatic reserve for patients with hepatocellular carcinoma and Child-Pugh B cirrhosis.
Terashima T; Yamashita T; Arai K; Kawaguchi K; Kitamura K; Yamashita T; Sakai Y; Mizukoshi E; Honda M; Kaneko S
Cancer Sci; 2016 Sep; 107(9):1263-9. PubMed ID: 27315783
[TBL] [Abstract][Full Text] [Related]
17. Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
An C; Fu Y; Li W; Zuo M; Wu P
Cancer; 2023 Jul; 129(14):2235-2244. PubMed ID: 37029486
[TBL] [Abstract][Full Text] [Related]
18. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A.
Lee BH; Lee DS; Cho CW; Yun SS
World J Surg Oncol; 2019 Aug; 17(1):143. PubMed ID: 31416447
[TBL] [Abstract][Full Text] [Related]
19. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma and Child-Pugh Class B: A Retrospective Cohort Study.
Ishii M; Itano O; Iwamoto H; Hibi T; Itano S
Oncology; 2022; 100(5):278-289. PubMed ID: 35184053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
